These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29353109)

  • 1. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
    Kasamon YL; Fuchs EJ; Zahurak M; Rosner GL; Symons HJ; Gladstone DE; Huff CA; Swinnen LJ; Brodsky RA; Matsui WH; Borrello I; Shanbhag S; Cooke KR; Ambinder RF; Luznik L; Bolaños-Meade J; Jones RJ
    Biol Blood Marrow Transplant; 2018 May; 24(5):1022-1028. PubMed ID: 29353109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
    DeZern AE; Elmariah H; Zahurak M; Rosner GL; Gladstone DE; Ali SA; Huff CA; Swinnen LJ; Imus P; Borrello I; Wagner-Johnston ND; Ambinder RF; Brodsky RA; Cooke K; Luznik L; Fuchs EJ; Bolaños-Meade J; Jones RJ
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2075-2081. PubMed ID: 32818556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
    McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
    Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
    Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
    Kasamon YL; Bolaños-Meade J; Prince GT; Tsai HL; McCurdy SR; Kanakry JA; Rosner GL; Brodsky RA; Perica K; Smith BD; Gladstone DE; Swinnen LJ; Showel MM; Matsui WH; Huff CA; Borrello I; Pratz KW; McDevitt MA; Gojo I; Dezern AE; Shanbhag S; Levis MJ; Luznik L; Ambinder RF; Fuchs EJ; Jones RJ
    J Clin Oncol; 2015 Oct; 33(28):3152-61. PubMed ID: 26261255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
    Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
    Elmariah H; Kasamon YL; Zahurak M; Macfarlane KW; Tucker N; Rosner GL; Bolaños-Meade J; Fuchs EJ; Wagner-Johnston N; Swinnen LJ; Huff CA; Matsui WH; Gladstone DE; McCurdy SR; Borrello I; Gocke CB; Shanbhag S; Cooke KR; Ali SA; Brodsky RA; DeZern AE; Luznik L; Jones RJ; Ambinder RF
    Biol Blood Marrow Transplant; 2018 May; 24(5):1099-1102. PubMed ID: 29452245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil.
    Esquirol A; Pascual MJ; Montoro J; Piñana JL; Ferrà C; Herruzo B; Garcia-Cadenas I; Balaguer A; Perez A; Huguet M; Redondo S; Villalba M; Hernandez-Boluda JC; Chorao P; Hernani R; Sanz J; Solano C; Sierra J; Martino R
    Transplant Cell Ther; 2024 Oct; 30(10):1025.e1-1025.e14. PubMed ID: 39116938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Haris Ali ; Shukaib Arslan ; Dimaggio E; Gonzalez R; Shouse G; Pourhassan H; Taiga Nishihori ; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Ryotaro Nakamura ; Pidala J; Guido Marcucci ; Stephen J Forman ; Anasetti C; Bejanyan N; Monzr M Al Malki
    Transplant Cell Ther; 2024 Oct; 30(10):1019.e1-1019.e9. PubMed ID: 39102983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
    McCurdy SR; Kanakry JA; Showel MM; Tsai HL; Bolaños-Meade J; Rosner GL; Kanakry CG; Perica K; Symons HJ; Brodsky RA; Gladstone DE; Huff CA; Pratz KW; Prince GT; Dezern AE; Gojo I; Matsui WH; Borrello I; McDevitt MA; Swinnen LJ; Smith BD; Levis MJ; Ambinder RF; Luznik L; Jones RJ; Fuchs EJ; Kasamon YL
    Blood; 2015 May; 125(19):3024-31. PubMed ID: 25814532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
    Luznik L; O'Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; Huff CA; Matsui W; Bolaños-Meade J; Borrello I; Powell JD; Harrington E; Warnock S; Flowers M; Brodsky RA; Sandmaier BM; Storb RF; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):641-50. PubMed ID: 18489989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
    Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
    Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.